These finding suggest that while co-targeting MEK and mTOR is effective for tumor reduction in all HNSCC models tested, PIK3CA expression specifically sensitizes HNSCC cells to the pro-apoptotic activity of MEK and mTOR combined targeted treatment, thereby displaying increased response. This evidence concerns the gene MAP2K7 and neoplasm.